Home Se-Cure: A Home Care Service for Cancer Patients during the COVID-19 Pandemic.
Tania Buttiron WebberSilvia GiulianoCarlotta PatroneIrene Maria BriataMaria FranconeriFrancesca MarcecaMonica MagnaniFortuna PaciollaNicoletta ProvincialiCarlotta DefferrariMatteo ClavarezzaMauro D'AmicoAlberto GozzaMonica BoitanoMattia Alessio MazzolaIsabella CevascoAndrea DeCensiPublished in: International journal of environmental research and public health (2021)
Cancer patients are exposed to a greater risk of COVID-19 infection, resulting in treatment delays and unnecessary hospitalizations. International authorities have suggested reducing visits to hospitals and guarantee continuity of care. We developed a home care project called Home Se-Cure (HSC) to guarantee the continuity of oral, intramuscular, and subcutaneous cancer therapy during COVID-19. The Home Se-Cure project included cancer patients living near Galliera Hospital. Patients received home visits by registered nurses (RNs), whoperformed blood tests and delivered cancer therapies. Patients were instructed to take drugs after blood test results and therapy confirmation by oncologists. Sixty-six patients decided to participate and 38 declined the service. A customer satisfaction questionnaire was administered to a subgroup of patients participating in the project. The most prevalent disease in the HSC group was prostate cancer. The mean age of the patients in HSC was 78.4 years and 68.9 in the decliner group. The majority of the HSC participants appreciated the project because they could stay at home (71%) and reduce the risk of COVID-19 contagion (67.7%). Compared to decliners, the time the study group saved was 2033 hours. HSC guaranteed the continuity of care during the COVID-19 pandemic by reducing the number of patients in the hospital and avoiding crowds in the waiting room.
Keyphrases
- end stage renal disease
- healthcare
- prostate cancer
- newly diagnosed
- peritoneal dialysis
- quality improvement
- coronavirus disease
- mental health
- palliative care
- randomized controlled trial
- squamous cell carcinoma
- emergency department
- drug delivery
- sars cov
- open label
- double blind
- electronic health record
- combination therapy